Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–76.

Article  PubMed  Google Scholar 

Fan L, Wu Y, Wei J, Xia F, Cai Y, Zhang S, et al. Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain. 2023;24(1):79.

Article  PubMed  PubMed Central  Google Scholar 

Headache Classification Committee of the International Headache Society (IHS) The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210.

Article  PubMed  Google Scholar 

Tsai CK, Tsai CL, Lin GY, Yang FC, Wang SJ. Sex differences in chronic migraine: focusing on clinical features, pathophysiology, and treatments. Curr Pain Headache Rep. 2022;26(5):347–55.

Article  PubMed  Google Scholar 

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–88.

Article  PubMed  Google Scholar 

Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.

PubMed  Google Scholar 

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–34.

Article  CAS  PubMed  Google Scholar 

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22.

Article  CAS  PubMed  Google Scholar 

Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. 2021;268(10):3789–98.

Article  PubMed  Google Scholar 

• Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61(2):363–72. Predictors in migraine.

•• Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22(1):35. Predictors in migraine and CM.

Ashina M, Amin FM, Kokturk P, Cohen JM, Konings M, Tassorelli C, et al. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Manag. 2021;11(6):647–54.

Article  PubMed  Google Scholar 

Murray AM, Stern JI, Robertson CE, Chiang CC. Real-world patient experience of CGRP-targeting therapy for migraine: a narrative review. Curr Pain Headache Rep. 2022;26(10):783–94.

Article  PubMed  Google Scholar 

Briceño-Casado MDP, Gil-Sierra MD, De-La-Calle-Riaguas B. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm. 2023;30(4):e19.

Article  PubMed  Google Scholar 

Overeem LH, Lange KS, Fitzek MP, Siebert A, Steinicke M, Triller P, et al. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol. 2023;14:1154420.

Article  PubMed  PubMed Central  Google Scholar 

•• Iannone LF, Burgalassi A, Vigani G, Tabasso G, De Cesaris F, Chiarugi A, et al. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia 2023;43(4):03331024231160519. Predictors in CM.

Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, et al. CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr Pain Headache Rep. 2019;23(5):29.

Article  PubMed  Google Scholar 

Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24(2):91–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(1):67.

Article  PubMed  PubMed Central  Google Scholar 

Wang YF, Wang SJ. CGRP Targeting therapy for chronic migraine—evidence from clinical trials and real-world studies. Curr Pain Headache Rep. 2022;26(7):543–54.

Article  CAS  PubMed  Google Scholar 

Informe de Posicionamiento Terapéutico de erenumab (Aimovig®) en la profilaxis de migraña. https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-erenumab-Aimovig.pdf.

Informe de Posicionamiento Terapéutico de galcanezumab (Emgality®) en la profilaxis de migraña. https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-galcanezumab-Emgality.pdf.

Informe de posicionamiento terapéutico de fremanezumab (Ajovy®) en la profilaxis de la migraña. https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT_11-2020-fremanezumab-Ajovy.pdf.

Informe de Posicionamiento Terapéutico de eptinezumab (Viepty®) en la profilaxis de migraña. IPT-126-Vyepti-eptinezumab.pdf - svadcf.es

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.

Article  PubMed  PubMed Central  Google Scholar 

•• Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache. 2021;61(9):1351–63. Predictors in CM.

•• Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs. 2022;36(2):191–202. Predictors in CM.

•• Lee HC, Cho S, Kim BK. Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. Neurol Sci. 2023;44(7):2455–63. Predictors in CM.

•• Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K. Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation. J Headache Pain. 2022;23(1):86. Predictors in CM.

•• Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2022;43(2):1273–80. Predictors in CM.

•• Barbanti P, Egeo G, Aurilia C, Altamura C, d’Onofrio F, Finocchi C, et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23(1):138. Predictors in CM.

Peng KP, Basedau H, Oppermann T, May A. Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction. Pain. 2022;163(11):2194–9.

Article  CAS  PubMed  Google Scholar 

• Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11(8):e2260. Predictors in migraine.

Article  PubMed  PubMed Central  Google Scholar 

• Lekontseva O, Wang M, Amoozegar F. Predictors of clinical response to erenumab in patients with migraine. Cephalalgia Reports. 2022;5:251581632211281. Predictors in migraine.

Article  Google Scholar 

Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U. A Scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel). 2023;16(7):934.

Article  CAS  PubMed  Google Scholar 

Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24(1):23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand. 2021;144(3):325–33.

• Salem-Abdou H, Simonyan D, Puymirat J. Identification of predictors of response to Erenumab in a cohort of patients with migraine. Cephalalgia Reports. 202;4:25158163211026650. Predictors in migraine.

•• Gonzalez-Martinez A, Pagán J, Sanz-García A, García-Azorín D, Rodríguez-Vico JS, Jaimes A, et al. Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: a multicenter Spanish study. Eur J Neurol. 2022;29(10):3102–11. Predictors using a machine-learning approach and large sample size.

Article  PubMed  Google Scholar 

Cetta I, Messina R, Zanandrea L, Colombo B, Filippi M. Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study. Neurol Sci. 2022;43(9):5769–71.

Article  PubMed  Google Scholar 

Muñoz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023;24(1):63.

Article  PubMed  PubMed Central  Google Scholar 

Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285.

Article  PubMed  PubMed Central  Google Scholar 

• Zecca C, Cargnin S, Schankin C, Giannantoni NM, Viana M, Maraffi I, et al. Clinic and genetic predictors in response to erenumab. Eur J Neurol. 2022;29(4):1209–17. Predictors in migraine.

Recober A, Goadsby PJ. Calcitonin gene-related peptide (CGRP): a molecular link between obesity and migraine? Drug News Perspect. 2010;23(2):112–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, et al. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. Eur J Neurol. 2023;30(6):1764–73.

Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 2023;24(1):16.

Barad M, Sturgeon JA, Fish S, Dexter F, Mackey S, Flood PD. Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain. Reg Anesth Pain Med. 2019;44(6):660–8.

Article  PubMed  PubMed Central  Google Scholar 

•• Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et al. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2021. Predictors in CM.

González-Martínez A, Muro I, Quintas S, Chaparro M, Gisbert JP, Sanz-García A, et al. Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics. Gastroenterol Hepatol. 2023;S0210–5705(23)00331-X.

Arzani M, Jahromi SR, Ghorbani Z, Vahabizad F, Martelletti P, Ghaemi A, et al. Gut-brain axis and migraine headache: a comprehensive review. J Headache Pain. 2020;21(1).

Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, et al. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain. 2022;23(1):56.

Article  CAS  PubMed